FocalTherics Q2 Revenue Climbs 39%, but Net Loss Widens on $5.5M Warrant Charge
FOCL has more than doubled off its 52-week low of $1.3 on elevated volume (4.3× avg).
Summary
FocalTherics reported Q2 revenue of $13.2M, up 39% year-over-year, with 47% U.S. procedure growth. Net loss widened to $14.4M due to a $5.5M non-cash warrant fair-value charge. Guidance reiterated at $50-54M for 2026.
Key Events · Earnings and Guidance · FOCL
-
Q2 Revenue Up 39%
Total revenue reached $13.2M, up from $9.5M in Q2 2025, driven by 13 Focal One system sales (vs 9) and 47% growth in U.S. procedures.
-
Net Loss Widens on Warrant Charge
Net loss was $14.4M ($0.38/share) vs $6.4M a year ago, primarily due to a $5.5M non-cash fair-value loss on EIB warrant liability — a mark-to-market adjustment, not a cash outflow.
-
Cash Position and Guidance
Cash and equivalents totaled $21.5M at June 30, 2026. Management reiterated 2026 revenue guidance of $50.0-$54.0M, implying 34-45% growth.
-
Discontinued Operations
ESWL and Distribution segments are now classified as held for sale and reported as discontinued operations, leaving HIFU as the sole continuing segment.
Analysis · FOCL · Industrial Applications And Services
Final Q2 results confirm strong HIFU growth — revenue up 39% to $13.2M, gross margin improved to 55.6%, and 47% U.S. procedure growth. But the bottom line swung to a $14.4M net loss, driven by a $5.5M non-cash warrant liability fair-value adjustment tied to the European Investment Bank warrants. That charge is a mark-to-market accounting entry reflecting the higher share price, not a cash outflow or new dilution. Cash stands at $21.5M, and the company reiterated full-year guidance of $50-54M revenue. The ESWL and Distribution businesses are now classified as discontinued operations, making HIFU the sole continuing segment.
At the time of this filing, FOCL was trading at $4.59 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $178M. The 52-week trading range was $1.30 to $6.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.